Last updated on January 2020

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of Tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic ESCC.

Clinical Study Identifier: NCT03783442

Find a site near you

Start Over

Ashford Cancer Centre Research

Kurralta Park, Australia
  Connect »